IN8BIO, INC. Finance Lease, Liability, to be Paid, after Year Five
IN8BIO, INC. (INAB) had Finance Lease, Liability, to be Paid, after Year Five of $0 as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2025-03-13
- 2024-12-31: Finance Lease, Liability, to be Paid, after Year Five $0.00.
- 2023-12-31: Finance Lease, Liability, to be Paid, after Year Five $0.00.
- 2022-12-31: Finance Lease, Liability, to be Paid, after Year Five $0.00.
- 2021-12-31: Finance Lease, Liability, to be Paid, after Year Five $0.00.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |